Clinical Practice Guidelines
2.0.0-ballot - ballot International flag

This page is part of the Clinical Guidelines (v2.0.0-ballot: STU2 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 1.0.0. For a full list of available versions, see the Directory of published versions

Example ActivityDefinition: CHF LASIX PO Activity Defintion

Active as of 2023-12-19

Generated Narrative: ActivityDefinition

Resource ActivityDefinition "chf-lasix-po"

Profile: CPG Computable Activity Definition

CQF Knowledge capability: shareable

CQF Knowledge capability: computable

CQF Knowledge capability: publishable

CQF knowledge representation level: structured

StructureDefinition Work Group: cds

url: http://hl7.org/fhir/uv/cpg/ActivityDefinition/chf-lasix-po

version: 2.0.0-ballot

name: CHFLASIXPO

status: active

experimental: true

date: 2023-12-19 19:53:17+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: Activity definition to administer LASIX PO as part of a congestive heart failure pathway

jurisdiction: World (m49.htm#001)

kind: MedicationRequest

profile: CPG Medicaiton Request

code: Order a medication (CPG Activity Type Code System#order-medication)

intent: proposal

priority: routine

doNotPerform: false

product: LASIX PO (CHF Codes#lasix-po)

dosage

sequence: 1

text: 40mg

timing: Once per 1 days

route: Oral Route (qualifier value) (SNOMED CT#26643006)

doseAndRate